| Autor: |
Mirzaoglu M; Department of Obstetrics and Gynecology, Medical School, Firat University, Elazig, Turkey., Yavuzkir S; Department of Obstetrics and Gynecology, Medical School, Firat University, Elazig, Turkey., Mirzaoglu C; Department of Cardiology, Elazig Fethi Sekin City Hospital, Health Science University, Elazig, Turkey., Yurt N; Department of Obstetrics and Gynecology, Medical School, Firat University, Elazig, Turkey., Dagli AF; Department of Pathology, İzmir Bakircay University, İzmir, Turkey., Ozcan Yildirim S; Department of Histology and Embryology, Medical School, Firat University, Elazig, Turkey., Sahin İ; Department of Medical Biology, Medical School, Erzincan Binali Yildirim University, Erzincan, Turkey.; Department of Medical Biochemistry and Clinical Biochemistry, Firat Hormones Research Group, Medical School, Firat University, Elazig, Turkey., Aydin S; Department of Medical Biochemistry and Clinical Biochemistry, Firat Hormones Research Group, Medical School, Firat University, Elazig, Turkey. |
| Abstrakt: |
Asprosin (ASP) and subfatin are hormones that regulate glucose metabolism. The role of ASP and subfatin in serous ovarian tumors has not been investigated. We investigated the expression of subfatin and asprosin in 30 serous benign, 30 serous borderline, 30 malignant and 30 control ovarian tissues. We investigated ASP and subfatin immunoreactivity and quantification was achieved using an ELISA method. ASP and subfatin were localized in the epithelial parts of normal ovarian tissues; however, in cancer tissues, immunoreactivity was detected in the parenchymal areas. Biochemical analysis of ovarian tissues revealed significantly decreased ASP and subfatin compared to the control. We propose that ASP and subfatin are promising candidates for biomarkers to distinguish serous benign, serous borderline and malignant ovarian cancers. |
